Save Product
Product Details
Synonyms
Disintegrin and metalloproteinase domain-containing protein 9 (EC:3.4.24.-) Cellular disintegrin-related protein, Meltrin-gamma, Metalloprotease, disintegrin, cysteine-rich protein 9, Myeloma cell metalloproteinase, ADAM9, KIAA0021, MCMP, MDC9, MLTNG
Source
Human ADAM9, His Tag (AD9-H52H7) is expressed from human 293 cells (HEK293). It contains AA Ala 206 - Asp 697 (Accession # Q13443-1).
Predicted N-terminus: Ala 206
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 55.2 kDa. The protein migrates as 55-60 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Supplied as 0.2 μm filtered solution in 20 mM Tris, 500 mM NaCl, pH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
Shipping and Storage
This product is supplied and shipped on dry ice.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human ADAM9, His Tag on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-HPLC
The purity of Human ADAM9, His Tag (Cat. No. AD9-H52H7) was greater than 85% as determined by SEC-HPLC.
Bioactivity-ELISA
Immobilized Human ADAM9, His Tag (Cat. No. AD9-H52H7) at 1 μg/mL (100 μL/well) can bind Izeltabart with a linear range of 0.2-16 ng/mL (QC tested).
Protocol
Bioactivity
Measured by its ability to cleave a fluorogenic peptide substrate Mca-PLAQAV-Dpa-RSSSR-NH2. The specific activity is >25 pmol/min/µg (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
Disintegrin and metalloproteinase domain-containing protein 9
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
3 Details
- Highest Development Stage：
Phase 2 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
